| Assessment Status |
Rapid Review Complete |
| HTA ID |
21060 |
| Drug |
Molnupiravir |
| Brand |
Lagevrio® |
| Indication |
For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
| Rapid review commissioned |
30/11/2021 |
| Rapid review completed |
24/12/2021 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of molnupiravir compared with the current standard of care on the basis of the proposed price. |
